Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average EPS without NRI Growth Rate was 48.60% per year.
During the past 5 years, the average EPS without NRI Growth Rate was -2.10% per year.
During the past 10 years, the average EPS without NRI Growth Rate was -9.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Relief Therapeutics Holding was 80.50% per year. The lowest was -221.00% per year. And the median was 22.00% per year.
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Relief Therapeutics Holding 3-Year EPS without NRI Growth Rate Related Terms
XSWX:RLF vs KTTA, OSRH, LIMN: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Relief Therapeutics Holding's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Relief Therapeutics Holding 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Relief Therapeutics Holding's 3-Year EPS without NRI Growth Rate falls into.
Relief Therapeutics Holding 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 48.60% mean?
Relief Therapeutics Holding (XSWX:RLF) has a 3-Year EPS without NRI Growth Rate of 48.60% as of Jun. 2025. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Relief Therapeutics Holding and its competitors. This is 121% above median its historical median of 22.00.
Is Relief Therapeutics Holding's 3-Year EPS without NRI Growth Rate too high?
Relief Therapeutics Holding's current 3-Year EPS without NRI Growth Rate of 48.60% is 121% above median its 10-year median of 22.00. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.20. Relief Therapeutics Holding's value of 48.60% is 200% above this industry median. Overall, Relief Therapeutics Holding has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Relief Therapeutics Holding's 3-Year EPS without NRI Growth Rate compare to KTTA and OSRH?
Relief Therapeutics Holding's 3-Year EPS without NRI Growth Rate of 48.60% can be compared against companies in the Biotechnology industry. The industry median 3-Year EPS without NRI Growth Rate is 16.20. Relief Therapeutics Holding's value of 48.60% is 200% above this benchmark. While the company's 10-year median is 22.00 vs. the industry median of 16.20, Relief Therapeutics Holding has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.20, based on 1,159 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Relief Therapeutics Holding's current 3-Year EPS without NRI Growth Rate of 48.60% is 200% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Relief Therapeutics Holding and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Relief Therapeutics Holding's current 3-Year EPS without NRI Growth Rate is 48.60%, which is 121% above median its own 10-year median of 22.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relief Therapeutics Holding stock overvalued right now?
Relief Therapeutics Holding (XSWX:RLF) has a current 3-Year EPS without NRI Growth Rate of 48.60%. The stock's GF Value™ is CHF6.28, compared to a current price of CHF3.00 — trading 52.2% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 48.60%, which is 121% above median its 10-year median of 22.00 and 200% above the Biotechnology industry median of 16.20. Relief Therapeutics Holding's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Relief Therapeutics Holding (XSWX:RLF), the current 3-Year EPS without NRI Growth Rate is 48.60% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Relief Therapeutics Holding (XSWX:RLF) Overvalued in 2026?
Based on GuruFocus' analysis, Relief Therapeutics Holding stock appears to be undervalued.
The current stock price of CHF3.00 is trading 52.2% below its estimated GF Value™ of CHF6.28.
Key valuation signals for XSWX:RLF:
3-Year EPS without NRI Growth Rate: 48.60% (121% above median its 10-year median of 22.00)
GF Value™: CHF6.28 vs. price of CHF3.00 (52.2% below fair value)
Industry Position: 200% above the Biotechnology median
No single metric tells the full story. See the XSWX:RLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products, and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development, such as RLF-TD011 and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast, among others. Geographically, the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.
20GF Score
Get the complete analysis for XSWX:RLF
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:RLF has been successfully added to your 
